In recent years, AI has rapidly evolved as a tool to transform healthcare, improving diagnostics, personalizing treatment and improving patient outcomes. However, the use of health data for AI development poses significant legal and ethical challenges.
One of the fundamental issues with using health data for AI development is the tension between innovation and privacy. Privacy fears are particularly strong when it comes to sensitive health data shared across borders, as this can increase the risk of misuse and unauthorized access.
The rise of AI applications in healthcare has sparked new regulatory trends. Many US states are introducing AI-specific legislation, each establishing distinct standards and requirements for data processing, privacy and cybersecurity. National security is also a pressing issue, with the Biden administration highlighting the potential risks associated with sharing and releasing the country’s health data.
President Joe Biden’s executive order on AI, signed on October 30, 2023, aims to establish a comprehensive framework for the safe and ethical development of AI. Key elements of the decree include guiding AI research and development (R&D), ensuring data privacy, safeguarding national security, and mitigating bias in AI systems .
Privacy regulations are fragmented among states because each has its own set of consumer protection laws. Some states, such as California, have passed strict laws that place limits on the use of personal data, while others have minimal regulations. This fragmented landscape complicates compliance for companies operating nationally, making it difficult to standardize data practices.
In contrast, President-elect Donald Trump’s agenda, as outlined at the recent Republican National Convention, calls Biden’s executive order “dangerous,” saying it imposes “radical left-wing ideas” on state development. ‘AI. Trump’s position implies that Biden’s executive order is too restrictive and that the ideological elements it encompasses could hinder the United States’ competitive advantage in AI innovation.
During Trump’s first term as president, AI policy was not a priority, although he signed an executive order in 2019, marking the first US federal initiative prioritizing AI . This directive encouraged federal agencies to invest in AI R&D, highlighting the strategic interest in maintaining U.S. global technological leadership. At the time, technology experts were calling for a more robust U.S. AI strategy, especially as other countries, including members of the European Union, developed comprehensive national AI plans.
“Navigating Privacy, Regulatory, and the Political Divide in AI Healthcare” was originally created and published by Medical Device Networka brand owned by GlobalData.
The information on this website has been included in good faith for general information purposes only. It is not intended to constitute advice on which you should rely, and we make no representations, warranties, express or implied as to its accuracy or completeness. You should obtain professional or specialist advice before taking or refraining from any action on the basis of the content on our site.